Trial Profile
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients An Exploratory Single-Arm Phase II Clinical Trail
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Sep 2018 New trial record